Peptide Library

Human study PLS-00170

Association of thymosin β4 expression with clinicopathological parameters and clinical outcomes of bladder cancer patients.

Other design · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Association of thymosin β4 expression with clinicopathological parameters and clinical outcomes of bladder cancer patients.primary · Neoplasma · 2016-01-01 · PMID 27596300 · DOI

Design and participants

Design
Other design
Population
Patients with primary bladder transitional cell carcinoma (138 tissue specimens), with normal bladder tissue (24 specimens) for comparison.
Conditions
Bladder transitional cell carcinoma
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): The authors concluded that Tβ4 expression is correlated with the pathogenesis of bladder transitional cell carcinoma, and that patients with higher Tβ4 expression had shorter survival.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: The study measured endogenous tissue expression of Tβ4. It did not administer the compound, so it cannot inform its efficacy or safety.
    • abstract only: Only the PubMed abstract is available. Methods, funding and conflicts are not described.
    • inappropriate population: Study measured endogenous Tβ4 in tumour tissue and gave no Tβ4 treatment, so it does not address administration of the compound.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 27596300, abstract (sentences 8-9) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 27596300, abstract (sentence 3) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 27596300, abstract (sentence 3) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).